Main

Fecal microbiota transplantation involves the transfer of gut microbes, viruses and luminal content to modulate a recipient’s microbiome, for therapeutic purposes. While the efficacy of FMT has been demonstrated for various diseases1,2,3, such as recurrent Clostridioides difficile infection (rCDI)4,5 or ulcerative colitis (UC6,7), it may also facilitate microbiome recovery following disturbance8 and can enhance microbiome-mediated responses to other therapies9,10. Nevertheless, despite demonstrable efficacy in a growing range of clinical applications, the mode of action of FMT remains poorly understood3 and neither clinical success nor adverse outcomes are currently predictable with accuracy.

Because FMT primarily targets the microbiome, the engraftment of ‘beneficial’ and/or displacement of ‘detrimental’ microbes are expected to cause clinical effects3, in conjunction with more specific processes of host–microbiome interplay, such as the modulation of immune responses11, restored short-chain fatty acid (SCFA) metabolism12 or reinstated phage pressure13,14. It has been argued that both microbiome engraftment and clinical success are mainly determined by donor factors, and that rationally selected ‘super-donors’ may improve therapeutic efficacy15,16. This donor-centric view has since been questioned, at least for some indications17, highlighting the importance of recipient18,19,20 or procedural21 factors instead.

Changes in microbial compositions following FMT have been studied with regard to phages22 or fungi23,24, yet the bulk of current knowledge is focused on bacteria and archaea where colonization by donor microbes and the persistence of indigenous recipient microbes emerge at the strain level of microbial populations25. Strain-level studies suggest that colonization levels following FMT vary across indications: whereas donor and recipient strains coexist long term in metabolic syndrome (MetS) patients25, donor takeover is the most common outcome in rCDI26,27,28, with intermediate outcomes in UC29 or obesity30,31. However, the factors sha** these differential strain-level outcomes remain poorly understood. In small pilot study cohorts, colonization success of donor strains leading to short-term persistence was associated with species phylogeny, broad microbial phenotypes and relative fecal abundances in rCDI26,27, but with more adaptive metabolic phenotypes in UC32.

Here we conducted a meta-analysis of novel and published metagenomes from fecal samples collected before and after FMT to compare the fate of donor and recipient strain populations across multiple disease indications. We hypothesized that drivers of FMT response are best studied from an ecological perspective:33,34,5). d, Ternary diagram of the strain population space for conspecific recipient strain persistence, donor strain colonization, donor–recipient coexistence and influx of novel strains.